Navigation Links
Nephros Reports 2008 First Quarter Financial Results
Date:5/15/2008

ce company developing and marketing filtration products.

The Nephros HDF system is designed to improve the quality of life for the End-Stage Renal Disease (ESRD) patient while addressing the critical financial and clinical needs of the care provider. ESRD is a disease state characterized by the irreversible loss of kidney function. The Nephros HDF system removes a range of harmful substances more effectively, and with greater capacity, than existing ESRD treatment methods, particularly with respect to substances known collectively as "middle molecules." These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient.

The Nephros Dual Stage Ultrafilter (DSU) is the Company's line of water filtration products. The patented dual stage cold sterilization Ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses and parasites. The DSU proprietary design provides dual-stage filtration which reduces the risk of filtration failure. With an initial focus on health care, the DSU is in a pilot-use program at a major U.S. medical center and has been selected for further development by the U.S. Marine Corps.

Nephros products are sold and distributed throughout Europe and the Company's dialysis filters are currently being used in over fifty clinics in Europe.

For more information on Nephros please visit the Company's website, http://www.nephros.com.

Forward-Looking Statements

This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements include statements regarding the efficacy and intended use of the Company's technologies under development, the timelines for bringing such products to mark
'/>"/>

SOURCE Nephros, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Nephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008
2. Nephros Strengthens Commercialization Team with Addition of Marketing Executive
3. PreMD Reports First Quarter Results
4. Lifeway Foods Reports Record 1st Quarter 2008 Results
5. Corgenix Reports Third Quarter Fiscal 2008 Financial Results
6. Tiens Biotech Group (USA) Reports First Quarter Results
7. Cardiogenesis Reports First Quarter 2008 Results
8. STEN Corp. Reports 2008 Second-Quarter Revenue of $4.3 Million and Improved Results From Operations
9. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
10. The Female Health Company Reports 267% Increase in Second Quarter Earnings
11. NicOx Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... New research led by a scientist at the University ... key element in the development of the nervous system ... of breast cancer., A research team, led by ... the Department of Biology at York, has studied how ... tumours. These channels are found in the membranes of ...
(Date:4/23/2014)... April 24, 2014 Pregnant immigrants from Sub-Saharan ... increased monitoring during pregnancy, according to new research ... today in the British Journal of Obstetrics ... and eclampsia rates among immigrants and native-born women ... (Ontario), Denmark, Sweden, Spain (Catalonia and Valencia) and ...
(Date:4/23/2014)... O,Shea, M.D., scientific director at the National Institute of ... named the 2014 recipient of the Ross Prize in ... journal Molecular Medicine . The award will be ... of Sciences in Manhattan, followed by scientific presentations by ... of the National Institutes of Health. , The award, ...
(Date:4/23/2014)... Johns Hopkins scientists report that rats exposed to high-energy ... deep space mission, show lapses in attention and slower ... extremely low dose ranges. , The cognitive impairments ... of the animals appear to be linked to ... findings, if found to hold true in humans, suggest ...
(Date:4/23/2014)... compound that targets an important brain receptor has a ... including relapse behavior, a University at Buffalo animal study ... this may be a novel lead compound for treating ... UB research was published as an online preview article ... study, the compound, RO5263397, severely blunted a broad range ...
Breaking Medicine News(10 mins):Health News:Breast cancer replicates brain development process 2Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2
... AnaSpec, Accelrys, Almac Diagnostics, Seahorse Biosciences, BioFortis recognized for their ... ... San Francisco, CA (PRWEB) March 3, 2009 -- Cambridge ... that have won the Third Annual Best New Product ...
... drinks per day could increase a person,s risk of ... published in Cancer Epidemiology, Biomarkers and Prevention , ... , "Our findings support multiple nutrition recommendations that ... alcoholic beverages per day and women should limit intake ...
... article published recently by the American Journal of ... Ph.D., and colleagues show that a high-density of fast ... pounds in weight and .8 inches in waist circumference ... In contrast, high-walkability neighborhoods were associated with a decrease ...
... at the University of Pennsylvania School of Medicine ... source of immature cells that spur misplaced bone ... originates in blood vessels deep within skeletal muscle ... cells themselves. The work also shows that cells ...
... from Boston University found that multiple types of child ... based on a national multi-year study that explored the ... , The research, which appears in the ... binge drinking consuming five or more alcoholic drinks ...
... 3 The Sisters of Charity Health System (SCHS) ... letter of intent to modify their existing 50/50 not-for-profit ... and Mercy Medical Center in Canton. An equal 50/50 ... St. John West Shore Hospital with the addition of ...
Cached Medicine News:Health News:Best New Product Awards Winners Named at Molecular Medicine Tri-Conference 2Health News:Best New Product Awards Winners Named at Molecular Medicine Tri-Conference 3Health News:Fast-food density and neighborhood walkability affect residents' weight and waist size 2Health News:Misplaced metamorphosis 2Health News:How multiple childhood maltreatments lead to greater adolescent binge drinking 2Health News:How multiple childhood maltreatments lead to greater adolescent binge drinking 3Health News:Sisters of Charity Health System & University Hospitals Announce New Agreement for Jointly Owned Hospitals 2Health News:Sisters of Charity Health System & University Hospitals Announce New Agreement for Jointly Owned Hospitals 3Health News:Sisters of Charity Health System & University Hospitals Announce New Agreement for Jointly Owned Hospitals 4Health News:Sisters of Charity Health System & University Hospitals Announce New Agreement for Jointly Owned Hospitals 5
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Public/Private Sector Strategies for America,s Health Care Future (PS2) ... its report detailing how the state can reduce its ... areas that conservatively would save Florida taxpayers up to ... to identify steps the state could take that would ...
... EXTON, Pa., March 29, 2011 ViroPharma Incorporated (Nasdaq: ... Phase 2 clinical study to evaluate the safety and ... of acute antibody-mediated rejection (AMR) in recipients of donor-specific ... double blind, placebo-controlled study will evaluate the safety, tolerability ...
Cached Medicine Technology:Senate Receives Rx Blueprint Plan That Reduces Spending and Increases Quality 2ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR) 2ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR) 3ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR) 4ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR) 5
Manufacturer of the WellPro since 1992, ProGroup previously distributed the instrument through Denley and Labsystems. A direct replacement for the ProPette the WellPro performs serial dilutions in an...
... compatible with hood installations. ... system for 384-well plates, ... prepares large quantities of ... Wellpro also performs plate ...
... The Aquarius 384 is a ... Aquarius 384-well head is a unique ... washing using the included wash system. ... 250 microplate stacker system. Will ...
... new Nanopipetting System Genesis NPS based on ... allows you to miniaturize your assays for ... picking and direct dilutions., Furthermore it ... applications including gene expression analysis, gene mapping, ...
Medicine Products: